SEARCH

Current Edition

Alpha

Alpha Biopharma announces series A financing

 AZD3759, AlphaBio’s lead product, is a next-generation small molecule tyrosine kinase inhibitor (TKI). It is specifically designed to treat epidermal growth factor receptor (EGFR) mutation …

Continue Reading →